Clearside Biomedical reports Q3 loss of $0.08/share; XIPERE approval triggers $19M milestones

Clearside Biomedical, Inc.

2022-Q3 EPS reported -$0.32 revenue$3,888,000

XIPERE (triamcinolone acetonide) approved by FDA in Oct 2021 for macular edema associated with uveitis; first product for suprachoroidal injection.
Approval and pre-launch milestones from partners expected to provide $19M non-dilutive funding, extending cash runway into 2023.
Q3 2021 net loss $4.9M ($0.08 per share) vs $2.4M ($0.05 per share) in Q3 2020; revenue $3.1M vs $3.4M.
Cash and cash equivalents $25.2M as of Sep 30, 2021.
Phase 1/2a OASIS trial of CLS-AX (axitinib) in wet AMD completed dosing in Cohort 2; safety data expected by end of 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.